CEVOLUTION: A Randomized Phase III Trial Comparing Cevostamab Plus Pomalidomide and Dexamethasone (Pom-Dex) Versus Standard of Care (SOC) in Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - Sep 11, 2026 - Abstract #PA-069; Pres time: Sep 23, 2026; "Introduction: Efficacious new treatments are needed for RRMM patients (pts) with prior anti-CD38 antibody (Ab) and lenalidomide (len) exposure...In Arm B, pts will receive investigator's choice of either daratumumab plus pom-dex, elotuzumab plus pom-dex or carfilzomib plus dex, with the choice informed by the pts prior treatment exposure and refractoriness to individual classes of agents... CEVOLUTION is a pivotal Phase III trial that is expected to inform the clinical efficacy and safety of cevostamab plus pom-dex in pts with RRMM."
Clinical • P3 data • Hematological Malignancies • Multiple Myeloma
|
|
Rakesh Popat1; Adam D. Cohen2; Amrita Y. Krishnan3; Elena Zamagni4; Hira S. Mian5; Joshua Richter6; Sammy Chebon7; Diyva Samineni8; Kerstin Trunzer7; Tulika Tyagi8; Leanne Richardson9; Paresh Sewpaul9; Tina Nielsen7; Binod Dhakal10
|